VEN-HMA May Prolong Survival in Elderly Acute Myeloid Leukemia Population
Combining venetoclax (Venclexta) with hypomethylating agents (VEN-HMA) may boost survival in a subset of octo- and nonagenarian patients with acute myeloid leukemia (AML), according to findings from a retrospective study published in Blood Neoplasia. Among …